DrugPatentWatch Database Preview

GILEAD SCIENCES INC Company Profile

GILEAD SCIENCES INC has seventeen approved drugs.

There are sixty-five US patents protecting GILEAD SCIENCES INC drugs.

There are one thousand six hundred and eighty-five patent family members on GILEAD SCIENCES INC drugs in sixty-eight countries and two hundred and twenty-three supplementary protection certificates in seventeen countries.

International Patents:	1685
US Patents:	65
Tradenames:	16
Ingredients:	16
NDAs:	17
Drug Master File Entries:	7
Patent Litigation for GILEAD SCIENCES INC:	See patent lawsuits for GILEAD SCIENCES INC

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	VIREAD	tenofovir disoproxil fumarate	TABLET;ORAL	021356-001	Oct 26, 2001	AB	RX	Yes	Yes		➤ Sign Up				➤ Sign Up
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes	6,703,396*PED	➤ Sign Up			Y	➤ Sign Up
Gilead Sciences Inc	ODEFSEY	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	TABLET;ORAL	208351-001	Mar 1, 2016		RX	Yes	Yes	7,803,788	➤ Sign Up				➤ Sign Up
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-002	Jul 23, 2014		RX	Yes	Yes	9,149,477	➤ Sign Up				➤ Sign Up
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-002	Jul 23, 2014		RX	Yes	Yes	8,138,195	➤ Sign Up	Y	Y		➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	STRIBILD	cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	203100-001	Aug 27, 2012	5,914,331*PED	➤ Sign Up
Gilead Sciences Inc	STRIBILD	cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	203100-001	Aug 27, 2012	5,922,695*PED	➤ Sign Up
Gilead Sciences Inc	VIREAD	tenofovir disoproxil fumarate	TABLET;ORAL	021356-004	Jan 18, 2012	5,935,946*PED	➤ Sign Up
Gilead Sciences Inc	VIREAD	tenofovir disoproxil fumarate	TABLET;ORAL	021356-003	Jan 18, 2012	6,043,230*PED	➤ Sign Up
Gilead Sciences Inc	STRIBILD	cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	203100-001	Aug 27, 2012	5,935,946*PED	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	150 mg, 200 mg, and 250 mg	➤ Subscribe	2012-05-17
➤ Subscribe	Tablets	150 mg, 150 mg, 200 mg, 300 mg	➤ Subscribe	2018-10-04
➤ Subscribe	Tablets	300 mg	➤ Subscribe	2010-01-26
➤ Subscribe	Tablets	200 mg/25 mg/300 mg	➤ Subscribe	2015-05-20
➤ Subscribe	Tablets	150 mg	➤ Subscribe	2015-12-09

Subscribe to access the full database, or try a Free Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2430014	2016004	Norway	➤ Sign Up	PRODUCT NAME: LEDIPASVIR; REG. NO/DATE: EU/1/14/958 20141203
1663240	2015/052	Ireland	➤ Sign Up	PRODUCT NAME: A COMBINATION OF RILPIVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE HYDROCHLORIDE SALT OF RILPIVIRINE, AND EMTRICITABINE; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
2487166	122016000104	Germany	➤ Sign Up	PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON UND TENOFOVIRALAFENAMID ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/15/1061 20151119
1663240	CA 2015 00054	Denmark	➤ Sign Up	PRODUCT NAME: KOMBINATION AF RILPIVIRIN ELLER ETN TERAPEUTISK AEKVIVALENT FORM DERAF, SOM ER BESKYTTET AF GRUNDPATENTET, SASOM ET FARMACEUTISK ACCEPTABELT SALT AF RILPIVIRIN, HERUNDER HYDROCHLORIDSALTET AF RILPIVIRIN, OG EMTRICITABIN; REG. NO/DATE: EU/1/11/737/001-002 20111128
1632232	PA2016042	Lithuania	➤ Sign Up	PRODUCT NAME: RILPIVIRINO HIDROCHLORIDAS + EMTRICITABINAS + TENOFOVIRO ALAFENAMIDAS; REGISTRATION NO/DATE: EU/1/16/1112 20160621
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.